Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings results on February 11, 2026 that fell short of analyst expectations. The Healthcare company reported earnings per…
Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings results on February 11, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $1.88, missing the consensus estimate of $2.09 by $0.21 per share. Revenue came in at $805.5M, beating the estimate of $786.7M.
Neurocrine Biosciences's stock moved following the earnings release. The stock currently trades at $126.07 with a market capitalization of $15.4B.
Current market data
NASDAQ · NBIX
$140.44
Down: -$2.09 · -1.49%
Live quote updated
Our Markets Team monitors market data, SEC filings, analyst actions, earnings releases, and corporate announcements to produce timely updates for investors.
Keep reading
analyst ·
analyst ·
analyst ·
earnings ·
